论文部分内容阅读
目的:分析比较肝素与低分子量肝素治疗原发性肾病综合征的疗效。方法:将在我院住院的原发性肾病综合征患者50例随机分为低分子量肝素组(LMHG)和普通肝素组(HG)。普通肝素组包括男性20例,女性5例;低分子量肝素组包括男性21例,女性4例。结果:治疗5周后,两组尿蛋白阴转率比较:LMHG组蛋白阴转17例,HG组为12例,两组无显著性差异(P>0.05)。有1例患儿在静脉应用普通肝素期间出现穿刺部位不易止血现象,停药后恢复,其余未见其他不良反应。结论:LMHG治疗儿童肾病综合征是安全的,并能促进尿蛋白阴转,减低尿蛋白排出,有利于血浆白蛋白的恢复,减少长期蛋白尿对肾脏的损害。
Objective: To compare and analyze the therapeutic effect of heparin and low molecular weight heparin in the treatment of primary nephrotic syndrome. Methods: Fifty patients with primary nephrotic syndrome who were hospitalized in our hospital were randomly divided into low molecular weight heparin group (LMHG) and unfractionated heparin group (HG). Unfractionated heparin group, including 20 males and 5 females; low molecular weight heparin group, including 21 males and 4 females. Results: After 5 weeks of treatment, the negative rate of urinary protein in the two groups were compared: 17 cases of LMHG histone negative conversion, 12 cases of HG group, no significant difference between the two groups (P> 0.05). In 1 case of children in the routine application of unfractionated heparin during the puncture site is not easy to stop bleeding, withdrawal after recovery, the rest no other adverse reactions. Conclusion: LMHG treatment of children with nephrotic syndrome is safe, and can promote urinary protein overcast, reduce urinary protein excretion, is conducive to the recovery of plasma albumin, reduce long-term proteinuria on the kidney damage.